Circulating Cell-Free Tumor DNA Market, by Tumor Type (Malignant Tumors, Precancerous Tumors), by Cancer Type (Lung Cancer, Colorectal Cancer, Breast Cancer, Others) by Technology (PCR, Massively Parallel Sequencing, Single Nucleotide Polymorphism), by Application (Cancer Diagnosis, Targeting Therapeutics, Prognosis Indication), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jun 2023

Code : CMI5819

Pages :190

Formats :

Excel and PDF

Industry : Biotechnology

Leading Companies

Global Circulating Cell-free Tumor DNA Market – Driver

Increasing product launches by key players in the market

Increasing product launches by key players in the market to expand their product portfolio is expected to drive market growth over the forecast period. For instance, Foundation Medicine, a manufacturer of genomic profiling assays based on next-generation sequencing technology, and Natera, a global leader in cell-free DNA (cfDNA) testing announced the launch of an early access program for the investigational and clinical use of FoundationOne Tracker, a personalized circulating tumor DNA (ctDNA) monitoring assay.

Global Circulating Cell-free Tumor DNA Market: Key Developments

Increasing research and development activities and product launch by key players in the market is expected to generate new opportunities in the global Circulating Cell-free Tumor DNA Market.
On 10 January 2023, Grail, a biotechnology company, announced the launch of a targeted methylation platform to analyze cell-free DNA (cfDNA) isolated from peripheral blood for cancer signal interrogation.
In August 2020, CLOVIS ONCOLOGY, a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) approved the FoundationOne Liquid CDx, Foundation Medicine’s comprehensive liquid biopsy test for all solid tumors with multiple companion diagnostic indications, including for Rubraca (rucaparib) tablets, recently approved for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer.
In October 2021, Natera, Inc., a global leader in cell-free DNA (cfDNA) testing announced the publication of a new study in Clinical Cancer Research demonstrating the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to assess tumor growth rates and predict patient survival in early-stage colorectal cancer (CRC).
In August 2021, Illumina, Inc. a biotechnology company, announced that it has acquired GRAIL, a healthcare company focused on the life-saving early detection of multiple cancers. GRAIL's Galleri blood test detects 50 different cancers before they are symptomatic. Illumina's acquisition of GRAIL will accelerate access and adoption of this life-saving test worldwide.